Qiagen Stock Price, News & Analysis

QIAGEN (NYSE: QGEN) has announced upcoming leadership changes in its Supervisory Board. Stephen H. Rusckowski, current Chair of the Nomination & Governance Committee, will succeed Lawrence A. Rosen as Chairman following the Annual General Meeting on June 26, 2025. Rosen, who has served since 2013 and as Chairman since 2020, will step down after the meeting.

Additionally, Prof. Dr. Elaine Mardis, who has served since 2014, will not seek re-election. All other current Supervisory Board members will stand for re-election to one-year terms. Following these changes, the Supervisory Board will be streamlined to eight members, aligning with a plan announced in 2024.

Rusckowski, who joined the board in 2023, brings significant healthcare industry experience as former Chairman, President and CEO of Quest Diagnostics and former CEO of Philips Healthcare.

QIAGEN reported strong Q1 2025 results with net sales of $483 million, representing a 5% growth at actual rates and 7% growth at constant exchange rates (CER). The company achieved an adjusted diluted EPS of $0.55, exceeding their outlook. The adjusted operating income margin improved to 29.8%, up 4.1 percentage points from Q1 2024. Key growth pillars QIAstat-Dx and QuantiFERON posted double-digit sales gains. QIAGEN reaffirmed its FY 2025 outlook for about 4% CER sales growth and upgraded adjusted EPS outlook to about $2.35 CER. The company plans to expand its capital allocation strategy by introducing a dividend and seeking approval for a new $500 million share repurchase program. Additionally, Stephen H. Rusckowski is proposed to become the new Chairman of the Supervisory Board.

QIAGEN (NYSE: QGEN) has announced plans to initiate its first-ever annual cash dividend program, subject to shareholder approval at the Annual General Meeting on June 26, 2025. The initial proposed dividend is $0.25 per ordinary share, amounting to a total payout of approximately $54 million.

The record date is planned for July 2, 2025, with payment scheduled for July 10, 2025. The amended dividend policy aims to balance shareholder returns with maintaining flexibility for growth investments, considering factors such as distributable profits, R&D investments, working capital needs, and potential M&A opportunities.

[ "Introduction of first-ever dividend program showing financial strength", "Total dividend payout of $54 million to enhance shareholder returns", "Flexible dividend policy allowing balance between shareholder returns and growth investments" ]

QIAGEN has expanded its digital PCR portfolio with new solutions for lentivirus-based cell and gene therapies. The company introduced key products including the QIAcuity RCL Quant Kit for safety testing, new CGT dPCR assays for viral measurements, and a specialized Lentivirus Lysis Kit for improved workflow.

The expansion specifically targets quality control in the manufacturing of advanced treatments like CAR-T cell therapy, a personalized cancer immunotherapy. The new offerings provide:

• Enhanced detection of replication-competent lentivirus
• Eight different wet-lab verified lentiviral targets
• Improved accuracy in viral titer measurement
• Streamlined protocols for vector copy number determination

This portfolio enhancement strengthens QIAGEN's position as a quality control partner for biotech companies, CDMOs, and therapy developers. The solutions complement existing products for residual DNA quantification, mycoplasma testing, and viral vector analysis, supporting the growing cell and gene therapy industry's regulatory compliance needs.

QIAGEN (NYSE: QGEN) has announced significant updates to its cancer genomic profiling portfolio at the AACR Annual Meeting 2025. The company unveiled new QIAseq panels for comprehensive genomic profiling, capable of analyzing over 700 genes for research and clinical applications.

Key developments include:

• Expansion of QIAseq xHYB CGP portfolio with DNA and RNA panels
• Launch of QIAcuity RCL Quant Kit and CGT dPCR assays for cell and gene therapy quality control
• Partnership with Element Biosciences to integrate QIAseq xHYB CGP Panels into their Trinity workflow
• Collaboration with Myriad Genetics to develop a new sequencing-based HRD assay planned for 2025 launch
• Introduction of HSMD Research, a free, version of the Human Somatic Mutation Database covering 25 key genes in cancer research

QIAGEN (NYSE: QGEN) has announced plans to launch three new sample preparation instruments between 2025 and 2026. The flagship QIAsymphony Connect, scheduled for phased launch in 2025, will feature enhanced capabilities for oncology and genomics workflows, processing up to 96 samples simultaneously with improved automation and digital connectivity.

The QIAsprint Connect, launching in 2026, will be QIAGEN's first high-throughput system, capable of processing 192 samples per run with less than 30 minutes hands-on time, scaling up to 600 samples daily. The system reduces plastic waste by 50% and supports various sample types including plant, microbial, soil, and human tissues.

The QIAmini, also set for 2026 launch, targets the low-throughput segment, offering smaller labs an entry point into automation. These launches complement QIAGEN's existing automation portfolio, including the QIAcube Connect and EZ2 Connect systems.

QIAGEN N.V. (NYSE: QGEN) has announced its upcoming first quarter 2025 financial results release and conference call schedule. The company will release its Q1 2025 results on Wednesday, May 7, 2025, after market close at 22:05 Frankfurt time. A conference call is scheduled for Thursday, May 8, at 15:00 Frankfurt time, with dial-in options available for US, UK, and German investors. The company will provide a webcast option and call-back service for participants, with replay access available after the event.

QIAGEN (NYSE: QGEN) reported strong preliminary Q1 2025 results, with net sales growing 7% at constant exchange rates (CER) to approximately $483 million, exceeding the previous outlook of 3% CER growth. Adjusted diluted EPS is expected to be at least $0.55 CER, surpassing the earlier guidance of $0.50 CER.

Key growth drivers include:

• QuantiFERON latent TB test: ~15% CER growth
• QIAstat-Dx syndromic testing system: >35% CER growth
• QIAcuity digital PCR system and QIAGEN Digital Insights: high-single-digit CER gains

Based on strong Q1 performance, QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to approximately $2.35 CER (up from $2.28 CER). The company expects to achieve its mid-term adjusted operating income margin target of 31% ahead of the original 2028 timeline.

QIAGEN (NYSE:QGEN) reports strong preliminary Q1 2025 results, exceeding previous guidance. Net sales grew approximately 5% (+7% at constant exchange rates) to about $483 million, surpassing the outlook of 3% CER growth.

The company's QuantiFERON latent TB test saw ~15% CER growth, while the QIAstat-Dx syndromic testing system advanced above 35% CER. The QIAcuity digital PCR system and QIAGEN Digital Insights both achieved high-single-digit CER gains. Sample technologies sales declined 1% CER due to cautious instrument spending among Life Sciences customers.

QIAGEN has raised its full-year 2025 adjusted diluted EPS outlook to $2.35 CER from $2.28 CER, while maintaining its goal to improve adjusted operating income margin to above 30%. Q1 2025 adjusted diluted EPS is expected to be at least $0.55 CER, exceeding the previous outlook of $0.50 CER.